T3 Companies’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-15,000
Closed -$1.65K – 276
2026
Q2
$1.65K Buy
+15,000
New +$1.55K ﹤0.01% 170

Other funds holding DMAAR

T3 Companies's DMAAR Position: Q3 2026 in Review

T3 Companies sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q3 2026, closing a stake of 15,000 shares — an estimated $1.65K sold.

T3 Companies first reported a position in DMAAR in Q2 2026 and held it in 1 quarter. The position peaked at $1.65K in Q2 2026. 32 funds tracked by Wall St. Rank hold DMAAR as of Q3 2026.

  • T3 Companies reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q3 2026 after selling out during the quarter.
  • T3 Companies sold 15,000 Drugs Made In America Acquisition Corp Rights shares in Q3 2026, an estimated $1.65K.
  • T3 Companies first reported a position in Drugs Made In America Acquisition Corp Rights in Q2 2026 and held it in 1 quarter.
  • T3 Companies's Drugs Made In America Acquisition Corp Rights position peaked at $1.65K in Q2 2026.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q3 2026.

Based on T3 Companies's 13F filing for Q3 2026, filed 22 Oct 2026.